RejuvenAir Lobectomy for Safety and Histology

Lung Neoplasms Clinical Trial

— LobectomyCAN  

Official title:

A Prospective Study of RejuvenAir System Radial Spray Cryotherapy to Determine Safety and Delayed Histological Effect in the Lung

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02483052
• Other study ID #: 013
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 24, 2015
• Last updated: May 10, 2017
• Start date: August 2015
• Est. completion date: February 2016

Study information

• Verified date: May 2017
• Source: CSA Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RejuvenAir System treatment will be performed during preoperative bronchoscopy 2 to 90 days prior to prescheduled lung resection in Subjects requiring lobectomy for removal of peripheral tumors. Treatment will be limited to areas of the bronchi within the lobe that will be removed, distal to the anticipated margin of resection. Treatment should be at least 1 cm from the bronchial resection margins and away from the tumor bed. Treated airways will be inspected via bronchoscopy at the time of thoracotomy, and examined histologically following surgical resection. Subject participation will be from 1 to 90 days and enrollment is anticipated to take 3 months. Subject having a RejuvenAir procedure and not going on to a resection for any reason will be followed for a maximum of 90 days for safety and undergo bronchoscopic evaluation of the treated airways at 90 days (+/- 4 Days)) post treatment.

Description:

The study is a prospective, open label, single arm, single center study. The objective is to study the safety of the RejuvenAir System in a population of subjects who are scheduled to undergo a planned lobectomy. A secondary objective is to determine the histological effects of RejuvenAir System treatment in the airways. The Primary Endpoint is Safety as measured by occurrence of serious adverse events related to metered dose radial spray cryotherapy treatment performed prior to scheduled lobectomy surgery. The patient population intended to participate in this study are subjects scheduled to undergo lobectomy for peripheral lung lesions suspicious for or known to be cancer. Secondarily, this will enable an understanding of the histological characteristics and healing outcomes post-treatment in the airways, which will be resected. CSA Medical has conducted bench and animal studies that support the use of the RejuvenAir System as sufficiently safe and effective to warrant advancing the product into this primary safety study in patients presenting for consideration of lobectomy. Such patients provide a safe population to further the clinical evaluation of the system in that these subjects will receive their lobectomy or procedure 2 to 14 days following delivery of their metered liquid nitrogen treatment. At the time of their metered liquid nitrogen treatment they will be in an operating room setting with their thoracic surgeon in attendance. It is anticipated that subjects who agree to participate in this study will have the metered liquid nitrogen treatment at the time of evaluation of their lung lesion. This evaluation will include bronchoscopy with ultrasound for evaluation of their lymph nodes prior to the planned surgical resection of their lung abnormality.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• Males and females of 21 to 75 years of age.

• Subject is able to read, understand, and sign a written Informed Consent to participate in the study.

• Subject is scheduled within 90 days from date of study treatment for a lobectomy unrelated to this study (upper and lower lobes only). Preferred range is 2-14 days from study treatment.

• Subject has a pre-procedure post bronchodilator FEV1 of greater than or equal to 40% of predicted.

• Subject is able to undergo bronchoscopy in the opinion of the investigator or per hospital guidelines.

• Subject is able to adhere to and undergo a scheduled bronchoscope procedure prior to their clinically scheduled lobectomy surgical procedure.

Exclusion Criteria:

• • Subject is pregnant, nursing, or planning to get pregnant during study duration.

• Subject is scheduled to have a pneumonectomy or has had a previous contralateral pneumonectomy.

• Subject has had prior radiation therapy which involved the lungs.

• Subject has received chemotherapy within the past 6 months, or is anticipated to be treated with chemotherapy between initial study treatment and lobectomy procedure.

• Subject has an acute pulmonary infection or pneumonia within 6 weeks prior to study bronchoscopy.

• Subject has had COPD exacerbation within 6 weeks prior to study bronchoscopy.

• Subject has bronchiectasis in the area to be treated.

• Subject has bullous emphysema. Characterized as large bullae >3 centimeters and confirmed on CT.

• Subject has had a Lung transplant.

• Subject has had lung reduction surgery, including implanted emphysema stent (s) implanted, coils or other devices for treatment.

Related Conditions & MeSH terms

• Lung Neoplasms
• Neoplasms
• Pulmonary Neoplasms

Intervention

Device:
• RejuvenAir
RejuvenAir

Locations

Country	Name	City	State
Canada	William Osler Health System	Brampton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
CSA Medical, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety measured by occurrence of serious adverse events related to metered dose radial spray cryothreapy		prior to lobectomy-up to 14 days
Secondary	Histology assessed by description of depth of histological treatment effect per specified treatment dose		up to 90 days